Beyond Air, Inc. (NASDAQ:XAIR – Free Report) – Equities researchers at Roth Capital upped their FY2029 EPS estimates for shares of Beyond Air in a research note issued on Tuesday, June 17th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $0.11 per share for the year, up from their previous forecast of $0.06. The consensus estimate for Beyond Air’s current full-year earnings is ($0.79) per share. Roth Capital also issued estimates for Beyond Air’s FY2030 earnings at $0.19 EPS.
Beyond Air (NASDAQ:XAIR – Get Free Report) last posted its quarterly earnings results on Tuesday, June 17th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. Beyond Air had a negative net margin of 1,258.46% and a negative return on equity of 213.97%. The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $1.39 million.
Beyond Air Price Performance
Institutional Trading of Beyond Air
Large investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in Beyond Air during the 1st quarter worth $31,000. Squarepoint Ops LLC acquired a new stake in Beyond Air during the 4th quarter worth $48,000. Wealthedge Investment Advisors LLC acquired a new stake in Beyond Air during the 4th quarter worth $80,000. Geode Capital Management LLC boosted its stake in Beyond Air by 81.0% during the 4th quarter. Geode Capital Management LLC now owns 562,713 shares of the company’s stock worth $202,000 after purchasing an additional 251,823 shares during the period. Finally, Kingdon Capital Management L.L.C. boosted its stake in Beyond Air by 65.0% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 936,683 shares of the company’s stock worth $255,000 after purchasing an additional 369,157 shares during the period. Institutional investors and hedge funds own 31.50% of the company’s stock.
About Beyond Air
Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.
Further Reading
- Five stocks we like better than Beyond Air
- 3 REITs to Buy and Hold for the Long Term
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- Dividend Payout Ratio Calculator
- Overheated Market? Analysts Watch These Red Flags
- What is a Death Cross in Stocks?
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.